Gear Up for Insulet (PODD) Q1 Earnings: Wall Street Estimates for Key MetricsZacks Investment Research • 05/06/24
Wall Street Analysts See a 38.87% Upside in Insulet (PODD): Can the Stock Really Move This High?Zacks Investment Research • 03/28/24
Insulet's Randomized Controlled Trial (OP5-003) Demonstrates Omnipod® 5 Automated Insulin Delivery System is Superior to Pump TherapyBusiness Wire • 03/08/24
Insulet to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)Business Wire • 03/05/24
Down -15.31% in 4 Weeks, Here's Why You Should You Buy the Dip in Insulet (PODD)Zacks Investment Research • 02/27/24
Insulet Reports Full Year 2023 Revenue Increase of 30% (30% Constant Currency1) and Fourth Quarter 2023 Revenue Increase of 38% Year-Over-Year (37% Constant Currency)Business Wire • 02/22/24
Countdown to Insulet (PODD) Q4 Earnings: A Look at Estimates Beyond Revenue and EPSZacks Investment Research • 02/19/24